Vinorelbine Free Base | CAS# 71486-22-1 (free base) | vinca alkaloid

MedKoo Cat#: 414170 | Name: Vinorelbine Free Base

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Vinorelbine is a semi-synthetic vinca alkaloid that inhibits microtubule polymerization by binding to tubulin, specifically disrupting the formation of the mitotic spindle during cell division. This leads to cell cycle arrest in the M-phase and induces apoptosis, making it an effective antimitotic chemotherapeutic agent. Vinorelbine is primarily used in the treatment of non-small cell lung cancer (NSCLC) and metastatic breast cancer, often in combination with other chemotherapy agents.

Chemical Structure

Vinorelbine Free Base

CAS#71486-22-1 (free base)

Theoretical Analysis

MedKoo Cat#: 414170

Name: Vinorelbine Free Base

CAS#: 71486-22-1 (free base)

Chemical Formula: C45H54N4O8

Exact Mass: 778.3942

Molecular Weight: 778.95

Elemental Analysis: C, 69.39; H, 6.99; N, 7.19; O, 16.43

Price and Availability

Size	Price	Availability	Quantity
50mg	USD 650.00	2 Weeks
100mg	USD 1,050.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

125317-39-7 (tartrate) 105661-07-2 (tartrate 1:1) 71486-22-1 (free base)

Synonym

Vinorelbine Free Base; HSDB7665; HSDB-7665; HSDB 7665; Vinorelbine

IUPAC/Chemical Name

Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-((2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino(4,3-b)indol-8-yl)-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2beta,3beta,4beta,5alpha,12beta,19alpha)-

InChi Key

GBABOYUKABKIAF-AWKRZJOVSA-N

InChi Code

InChI=1S/C45H54N4O8/c1-8-27-19-28-22-44(40(51)55-6,36-30(25-48(23-27)24-28)29-13-10-11-14-33(29)46-36)32-20-31-34(21-35(32)54-5)47(4)38-43(31)16-18-49-17-12-15-42(9-2,37(43)49)39(57-26(3)50)45(38,53)41(52)56-7/h10-15,19-21,28,37-39,46,53H,8-9,16-18,22-25H2,1-7H3/t28-,37-,38+,39+,42+,43-,44-,45-/m0/s1

SMILES Code

[H][C@@]1([C@](C(OC)=O)(O)[C@H](OC(C)=O)[C@@]2(C=CCN3CC[C@@]41[C@@]32[H])CC)N(C)C5=C4C=C([C@@]6(C(OC)=O)C[C@]7([H])C=C(CC)C[N@@](C7)CC8=C6NC9=C8C=CC=C9)C(OC)=C5

Appearance

Solid powder

Purity

>95% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 778.95 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Su W, Li J. Clinical efficacy and safety of sintilimab plus oral vinorelbine as first-line treatment for newly diagnosed stage IIIB-IV nonsmall cell lung cancer patients with performance status 2 or age ≥75 years. Anticancer Drugs. 2025 Feb 6. doi: 10.1097/CAD.0000000000001699. Epub ahead of print. PMID: 39908219. 2: Fortunati D, Montanari A, Viso M, Felizzia G, Warriner E, Bosaleh A, Rizzi A, Solernou V, López Marti J, Sobrero V, Flores P, Cacciavillano W, Schwartz M, Racca G, Rose A. Extra-renal non-cerebral malignant rhabdoid tumor in children: does maintenance chemotherapy play a role in survival? Medicina (B Aires). 2025;85(1):101-111. English. PMID: 39900054. 3: Sun L, Wang J, Yu H, Zhu X, Zhang J, Hu J, Yan Y, Zhang X, Zhu Y, Jiang G, Ding M, Zhang P, Zhang L. Selective inhibition of TGF-β-induced epithelial- mesenchymal transition overcomes chemotherapy resistance in high-risk lung squamous cell carcinoma. Commun Biol. 2025 Feb 1;8(1):152. doi: 10.1038/s42003-025-07595-x. PMID: 39893253; PMCID: PMC11787392. 4: Riestra AC, Urretavizcaya M, Ferro Uriguen A, Olariaga Sarasola O, Iglesias A, Camba Y, Asensio Bermejo A, Tames MJ. Monitoring of occupational exposure to hazardous medicinal products in robotic compounding. Eur J Hosp Pharm. 2025 Jan 31:ejhpharm-2024-004294. doi: 10.1136/ejhpharm-2024-004294. Epub ahead of print. PMID: 39890433. 5: Zhang Z, Zheng K, Zhang Z, Cao L, Lin L, Sun W, Qiu F. Lactobacillus gasseri LGV03-derived indole-3-lactic acid ameliorates immune response by activating aryl hydrocarbon receptor. Microb Cell Fact. 2025 Jan 30;24(1):34. doi: 10.1186/s12934-025-02662-8. PMID: 39885499; PMCID: PMC11780890. 6: Arockiaraj M, Jeni Godlin JJ, Radha S, Aziz T, Al-Harbi M. Comparative study of degree, neighborhood and reverse degree based indices for drugs used in lung cancer treatment through QSPR analysis. Sci Rep. 2025 Jan 29;15(1):3639. doi: 10.1038/s41598-025-88044-x. PMID: 39881149; PMCID: PMC11779869. 7: Falvo P, Gruener S, Orecchioni S, Pisati F, Talarico G, Mitola G, Lombardi D, Bravetti G, Winkler J, Barozzi I, Bertolini F. Age-dependent differences in breast tumor microenvironment: challenges and opportunities for efficacy studies in preclinical models. Cell Death Differ. 2025 Jan 27. doi: 10.1038/s41418-025-01447-1. Epub ahead of print. PMID: 39870804. 8: Freire APE, Skubitz KM. Clinical Benefit of Pegylated Liposomal Doxorubicin and High Prevalence of Pre-Existing Psychiatric Conditions in Patients with Desmoid-Type Fibromatosis. Cancers (Basel). 2025 Jan 17;17(2):293. doi: 10.3390/cancers17020293. PMID: 39858074; PMCID: PMC11763362. 9: Banchi M, Cox MC, Bandini A, Orlandi P, Tacchi C, Stefanelli F, Chericoni S, Bocci G. Linifanib alone and in combination with metronomic chemotherapy is active on cutaneous T-cell lymphoma cells by targeting the AKT/mTOR signaling pathway. Invest New Drugs. 2025 Jan 17. doi: 10.1007/s10637-024-01501-8. Epub ahead of print. PMID: 39821757. 10: García-Saenz JÁ, Rodríguez-Lescure Á, Cruz J, Albanell J, Alba E, Llombart A. Second-Line Treatment Options for Patients with Metastatic Triple-Negative Breast Cancer: A Review of the Clinical Evidence. Target Oncol. 2025 Jan 13. doi: 10.1007/s11523-024-01125-1. Epub ahead of print. PMID: 39806129. 11: Li Y, Li W, Liu Y, Peng Y, Tang J, Li X. Efficacy and safety of anlotinib combined with vinorelbine as second‑line treatment for elderly patients with advanced squamous cell lung carcinoma: A retrospective cohort. Mol Clin Oncol. 2024 Dec 19;22(2):21. doi: 10.3892/mco.2024.2816. PMID: 39776939; PMCID: PMC11706458. 12: Frenel JS, Mathiot L, Cropet C, Borcoman E, Hervieu A, Coquan E, De La Motte Rouge T, Saada-Bouzid E, Sabatier R, Lavaud P, Jimenez M, Legrand F, Le Saux O, Charafe E, Gonçalves A. Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open- label phase I/II study. J Immunother Cancer. 2025 Jan 7;13(1):e010708. doi: 10.1136/jitc-2024-010708. PMID: 39773562; PMCID: PMC11749830. 13: Nemours S, Solé C, Goicoechea I, Armesto M, Arestin M, Urruticoechea A, Rezola M, López IÁ, Schaapveld R, Schultz I, Zhang L, Lawrie CH. Use of Gain-of- Function Screening to Identify miRNAs Involved in Paclitaxel Resistance in Triple-Negative Breast Cancer. Int J Mol Sci. 2024 Dec 20;25(24):13630. doi: 10.3390/ijms252413630. PMID: 39769392; PMCID: PMC11728027. 14: Liu J, Zhang J, Li H, Song G, Di L, Jiang H, Yan Y, Wang H, Wang J, Liu X, Shao B, Li Q. Anlotinib in combination with metronomic chemotherapy in HER2-negative metastatic breast cancer: an observational and retrospective study. BMC Cancer. 2025 Jan 3;25(1):9. doi: 10.1186/s12885-024-13403-2. PMID: 39754078; PMCID: PMC11697748. 15: Li X, Chen F, Yang R, Song Z, Ma X, Sun L, Yuan S. Metabolomics-based combination of GH and NVB in the treatment of NSCLC lung cancer recurrence. J Cancer. 2025 Jan 1;16(1):265-278. doi: 10.7150/jca.102722. PMID: 39744563; PMCID: PMC11660129. 16: Zang M, Zheng J, An X, Li BO, Yang H, Erickson B, Kunz R, Littlefield BA. Eribulin Induction of Immunogenic Cell Death (ICD): Comparison With Other Cytotoxic Agents and Temporal Relationship of ICD Biomarkers. Anticancer Res. 2025 Jan;45(1):39-53. doi: 10.21873/anticanres.17391. PMID: 39740820. 17: Xiong W, Sun J, Gu Q, Xu T, Zhang L, Yuan Y. Pyrotinib Plus Taxanes or Vinorelbine for the Treatment of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Prospective Evaluation of Efficacy and Safety. Clin Breast Cancer. 2024 Dec 5:S1526-8209(24)00355-0. doi: 10.1016/j.clbc.2024.12.006. Epub ahead of print. PMID: 39721892. 18: Ju JA, Thompson KN, Annis DA, Mull ML, Gilchrist DE, Moriarty A, Chang KT, Stemberger MB, Noto MJ, Vitolo MI, Martin SS. Tubulin-Based Microtentacles Aid in Heterotypic Clustering of Neutrophil-Differentiated HL-60 Cells and Breast Tumor Cells. Adv Sci (Weinh). 2024 Dec 18:e2409260. doi: 10.1002/advs.202409260. Epub ahead of print. PMID: 39696759. 19: Iacoboni G, Pérez Raya M. Optimizing Real-World Outcomes in High-Risk Relapsed/Refractory (r/r) DLBCL with CAR T Cell Therapy: A Vodcast and Case Example. Oncol Ther. 2024 Dec 16. doi: 10.1007/s40487-024-00319-x. Epub ahead of print. PMID: 39680322. 20: Friis RB, Pappot H, Hjollund NH, McCulloch T, Holt MI, Persson GF, Wedervang K, Clausen MM, Wahlstrøm S, Hansen KH, Rasmussen TR, Dalton SO, Jakobsen E, Linnet H, Skuladottir H; Danish Lung Cancer Group. Remote Symptom Monitoring of Patients With Advanced Lung Cancer (The ProWide Study): A Randomized Controlled Trial. JCO Oncol Pract. 2024 Dec 10:OP2400562. doi: 10.1200/OP-24-00562. Epub ahead of print. PMID: 39657078.